EBITDA Margin % is calculated as EBITDA divided by its Revenue. TScan Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-27.28 Mil. TScan Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $0.98 Mil. Therefore, TScan Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -2,778.41%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
TScan Therapeutics EBITDA Margin % Related Terms
TScan Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for TScan Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCRX vs BSEM, BYSI, MCRB: EBITDA Margin % Comparison
For the Biotechnology subindustry, TScan Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TScan Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TScan Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TScan Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TScan Therapeutics (TCRX) has a EBITDA Margin % of -2,778.41% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TScan Therapeutics and its competitors. According to the industry distribution chart, TScan Therapeutics ranks #777 out of 945 companies in the Biotechnology industry, placing it in the top 82.2%.
Is TScan Therapeutics' EBITDA Margin % too high?
TScan Therapeutics' current EBITDA Margin % is -2,778.41%. Based on the distribution chart, TScan Therapeutics ranks #777 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TScan Therapeutics has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TScan Therapeutics' EBITDA Margin % compare to BSEM and BYSI?
According to the Biotechnology industry distribution chart, TScan Therapeutics ranks #777 out of 945 companies for EBITDA Margin %. This places TScan Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TScan Therapeutics and its competitors. TScan Therapeutics's current EBITDA Margin % is -2,778.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TScan Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TScan Therapeutics (TCRX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.68, compared to a current price of $0.84 — trading 50% below its estimated fair value. The current EBITDA Margin % is -2,778.41%. TScan Therapeutics' overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TScan Therapeutics (TCRX), the current EBITDA Margin % is -2,778.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TScan Therapeutics (TCRX) Overvalued in 2026?
Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued.
The current stock price of $0.84 is trading 50% below its estimated GF Value™ of $1.68.
GuruFocus considers TScan Therapeutics to be Possible Value Trap.
Key valuation signals for TCRX:
EBITDA Margin %: -2,778.41%
GF Value™: $1.68 vs. price of $0.84 (50% below fair value)
No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
48GF Score
Get the complete analysis for TCRX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRX has been successfully added to your 
